Literature DB >> 25814258

Rapamycin ameliorates brain metabolites alterations after transient focal ischemia in rats.

Anjali Chauhan1, Uma Sharma2, Naranamangalam R Jagannathan2, Yogendra Kumar Gupta3.   

Abstract

Rapamycin has been shown to protect against middle cerebral artery occlusion (MCAo) induced ischemic injury. In this study, the neuroprotective effect of rapamycin on the metabolic changes induced by MCAo was evaluated using nuclear magnetic resonance (NMR) spectroscopy of brain tissues. MCAo in rats was induced by insertion of nylon filament. One hour after ischemia, rapamycin (250 µg/kg, i.p.) in dimethyl sulfoxide was administered. Reperfusion was done 2h after ischemia. Twenty-four hours after ischemia phospholipase A2 (PLA2) levels and metabolic changes were assessed. Perchloric acid extraction was performed on the brain of all animals (n=7; sham, vehicle; DMSO and rapamycin 250 µg/kg) and the various brain metabolites were assessed by NMR spectroscopy. In all 44 metabolites were assigned in the proton NMR spectrum of rat brain tissues. In the vehicle group, we observed increased lactate levels and decreased levels of glutamate/glutamine, choline containing compounds, creatine/phosphocreatine (Cr/PCr), taurine, myo-inositol, γ-amino butryic acid (GABA), N-aspartyl aspartate (NAA), purine and pyrimidine metabolites. In rapamycin treated rats, there was increase in the levels of choline containing compounds, NAA, myo-inositol, glutamate/glutamine, GABA, Cr/PCr and taurine as compared to those of vehicle control (P<0.05). Rapamycin treatment reduced PLA2 levels as compared to vehicle group (P<0.05). Our findings indicated that rapamycin reduced the increased PLA2 levels and altered brain metabolites after MCAo. These protective effects might be attributed to its effect on cell membrane metabolism; glutamate induced toxicity and calcium homeostasis in stroke.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Focal cerebral ischemia; Metabolites; Middle cerebral artery occlusion; NMR spectroscopy; Rapamycin; Rapamycin (PubChem CID CAS 53123-88-9)

Mesh:

Substances:

Year:  2015        PMID: 25814258     DOI: 10.1016/j.ejphar.2015.03.006

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Biophysical review's 'meet the editors series'-a profile of Naranamangalam R. Jagannathan.

Authors:  Naranamangalam R Jagannathan
Journal:  Biophys Rev       Date:  2020-05-27

2.  Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model.

Authors:  Rheal A Towner; Rafal Gulej; Michelle Zalles; Debra Saunders; Nataliya Smith; Megan Lerner; Kathryn A Morton; Arlan Richardson
Journal:  Geroscience       Date:  2021-04-13       Impact factor: 7.713

3.  The pattern of brain metabolism in chronic steno-occlusive cerebral artery disease.

Authors:  Lingyan Meng; Zhaodi Huang; Hui Li
Journal:  Ann Transl Med       Date:  2022-09

4.  Exploring the biomarkers and therapeutic mechanism of kidney-yang deficiency syndrome treated by You-gui pill using systems pharmacology and serum metabonomics.

Authors:  Ruiqun Chen; Jia Wang; Chengbin Liao; Lei Zhang; Qian Guo; Xiufeng Wang
Journal:  RSC Adv       Date:  2018-01-03       Impact factor: 4.036

Review 5.  Neuroimaging Advances in Pediatric Stroke.

Authors:  Manus J Donahue; Nomazulu Dlamini; Aashim Bhatia; Lori C Jordan
Journal:  Stroke       Date:  2019-02       Impact factor: 7.914

Review 6.  Role of mTORC1 Controlling Proteostasis after Brain Ischemia.

Authors:  Maria J Perez-Alvarez; Mario Villa Gonzalez; Irene Benito-Cuesta; Francisco G Wandosell
Journal:  Front Neurosci       Date:  2018-02-15       Impact factor: 4.677

Review 7.  Dysregulation of mTOR Signaling after Brain Ischemia.

Authors:  Mario Villa-González; Gerardo Martín-López; María José Pérez-Álvarez
Journal:  Int J Mol Sci       Date:  2022-03-04       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.